Search

Your search keyword '"Amerio, Paolo"' showing total 441 results

Search Constraints

Start Over You searched for: Author "Amerio, Paolo" Remove constraint Author: "Amerio, Paolo"
441 results on '"Amerio, Paolo"'

Search Results

1. Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

4. 3D TEM and SEM-array tomography of Hailey-Hailey Disease human skin biopsies

5. Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)

6. Italian S3-Guideline on the treatment of atopic eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

7. Italian S3-Guideline on the treatment of atopic eczema Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

10. Burden of Disease in Real-Life Setting of Patients With Atopic Dermatitis: Italian Data From the MEASURE-AD Study

11. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

12. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

13. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

14. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

16. Pulsed Radiofrequency Electromagnetic Fields as Modulators of Inflammation and Wound Healing in Primary Dermal Fibroblasts of Ulcers.

17. The Effect of Anxiety on Intraoperative and Postoperative Pain in Patients Undergoing Dermatologic Surgery: Learn to Manage

19. Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real‐world study.

25. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

26. Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study).

28. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

33. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.

36. National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis

37. "Your Skin Tells You" Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference.

39. Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature

40. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study

41. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

42. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis

43. Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication

47. Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

49. Mental Health Consequences of the COVID-19 Pandemic Long-Term Exposure in Italian Dermatologists

50. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Catalog

Books, media, physical & digital resources